Table 3.
2008–2012 | 2013–2017 | |||||
---|---|---|---|---|---|---|
Outpatients (%) | Inpatients (%) | Statisticsa | Outpatients (%) | Inpatients (%) | Statisticsa | |
Ampicillin | 0.0 | 0.0 | n.s | 0.0 | 0.0 | n.s |
Azithromycin | 16.0 | 17.8 | n.s | 19.4 | 21.3 | n.s |
Clindamycin | 14.2 | 18.5 | n.s | 19.1 | 20.4 | n.s |
Ciprofloxacin | 7.1 | 25.4 | p < 0.001 | 8.3 | 29.9 | p = 0.038 |
SMX/TMPb | 3.3 | 19.4 | p = 0.031 | 2.6 | 20.8 | p < 0.001 |
Rifampicin | 0.8 | 1.3 | n.s | 0.6 | 0.9 | n.s |
Vancomycin | 0.0 | 0.0 | n.s | 0.0 | 0.0 | n.s |
Linezolid | 0.0 | 0.0 | n.s | 0.0 | 0.0 | n.s |
aComparison of resistance levels among isolates originating from outpatients and inpatients.
bSulfamethoxazole-trimethoprim.
n.s. not significant (p > 0.05).